Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Febit Achieves Sales Goals

Published: Thursday, March 16, 2006
Last Updated: Monday, March 27, 2006
Bookmark and Share
Febit successfully markets the GENIOM bioanalysis device.

Febit biotech gmbh has announced that it has successfully concluded the business year, meeting its sales goals for 2005.

Sales of GENIOM™, a biochip-driven nucleic acid analysis system, were on budget already in the year of Febit's re-establishment.

This development is based on the fundamental restructuring and re-establishment of Febit biotech gmbh in spring 2005 when the company moved into new quarters in the Heidelberg Technologiepark.

Since its reorganization, Febit is supported by Dietmar and Oliver Hopp, two experienced biotech investors interested in a favourable long-term development of the company.

Integrating its structural and financial basis, Febit's re-establishment was supported by Prof. Christof Hettich, an experienced consultant from the Rittershaus firm of Mannheim.

In October 2005 the management team around Cord F. Stahler, CEO of Febit biotech gmbh was expanded, a supervisory board was established and the headcount was gradually increased.

The team consisting of management, staff and supervisory board boasts know-how and skills in all relevant areas. 

Febit has become a valuable cooperation partner in the biotech field, which is illustrated by a number of licence agreements signed in late 2005.

From Oxford Gene Technology, Febit acquired a license for the southern array technique, a method of major impact in gene research, thus enhancing its position with respect to intellectual property on the global market.

In a license agreement with the German Cancer Reseach Center (DKFZ), Febit acquired the rights to an alternative high-efficacy DNA synthesis method for use in its GENIOM® platform.       

Dr. Jorg Hoheisel at the DKFZ strongly supports the GENIOM® platform, said, "This DNA analysis device offers tremendous flexibility and has an extraordinary potential. It is invaluable for many aspects of our work at the DKFZ."   

The product website went online recently, complementing the corporate website and broadening Febit´s internet information resources for customers, investors and the public.

In February 2005, the Febit facilities were substantially enlarged and the headcount will reach 50 at the end of 2006 in order to realize the expansion plans and to ensure reliable product quality and availability. 

Cord F. Stahler, Chief Executive Officer of Febit biotech gmbh is confident to generate substantial growth within 2006, "The changes we made in 2005 and our network allow us to rapidly expand our position on the international market."

"The global market of DNA analysis devices will keep growing substantially in the next years. Febit will participate in this growth due to significant product advantages and the market-readiness of GENIOM®."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Geniom Technology Applied to Targeted Next-Generation Sequencing
By enabling selective targeting, the Geniom® Biochip will allow researchers to sequence individual and well defined parts of genomes
Tuesday, July 24, 2007
Febit Establishes US Company
Febit launches the GENIOM biochip system in the US.
Tuesday, August 15, 2006
Scientific News
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Lose Weight, Escape the Eight: Weight-Based Cancer Risk
IARC has identified eight additional cancer sites linked to overweight and obesity.
Coffee Consumption Linked to Genes
Researchers have identified a gene that influences coffee consumption. The gene is thought to relate to caffeine breakdown.
Emerging Model of Cancer
Cancer acts cooperatively, making individual decisions but acting in unison; this insight is being used to create a computer model of cancer.
Biological Barcodes Using CRISPR
Using genome editing tools, researchers are getting closer to understand differentiation of various cell types during development.
Controlling DNA Repair
Scientists discover that DNA repair outcomes following CRISPR-Cas9 cleaving are non-random and can be harnessed to produce desired effects.
Demonstrating LNP Delivery of CRISPR Components
Intellia has presented data demonstrating in vivo gene editing ising liquid nanoparticles (LNPs) to deliver CRISPR/Cas9.
Gene Therapy Via Ultrasound
Research into a gene therapy approach called sonoporation could help combat heart disease and cancer.
Creating Embryos with 'Heteroplasmy'
New discovery in genetic research could lead to treatments for mitochondrial diseases.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!